| Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial SB Goldberg, SN Gettinger, A Mahajan, AC Chiang, RS Herbst, M Sznol, ... The lancet oncology 17 (7), 976-983, 2016 | 975 | 2016 |
| Management of brain metastases in tyrosine kinase inhibitor–naïve epidermal growth factor receptor–mutant non–small-cell lung cancer: a retrospective multi-institutional analysis WJ Magnuson, NH Lester-Coll, AJ Wu, TJ Yang, NA Lockney, NK Gerber, ... Journal of clinical oncology 35 (10), 1070-1077, 2017 | 417 | 2017 |
| A retrospective review of 1349 cases of sebaceous carcinoma T Dasgupta, LD Wilson, JB Yu Cancer 115 (1), 158-165, 2009 | 368 | 2009 |
| Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival JPS Knisely, BY James, J Flanigan, M Sznol, HM Kluger, VLS Chiang Journal of neurosurgery 117 (2), 227-233, 2012 | 343 | 2012 |
| Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document Y Lievens, M Guckenberger, D Gomez, M Hoyer, P Iyengar, I Kindts, ... Radiotherapy and Oncology 148, 157-166, 2020 | 335 | 2020 |
| Extended survival and prognostic factors for patients with ALK-rearranged non–small-cell lung cancer and brain metastasis KL Johung, N Yeh, NB Desai, TM Williams, T Lautenschlaeger, ND Arvold, ... Journal of Clinical Oncology 34 (2), 123, 2016 | 329 | 2016 |
| The inhibin/activin family of hormones and growth factors W Vale, A Hsueh, C Rivier, J Yu Peptide growth factors and their receptors II, 211-248, 1990 | 325 | 1990 |
| Use of alternative medicine for cancer and its impact on survival SB Johnson, HS Park, CP Gross, JB Yu JNCI: Journal of the National Cancer Institute 110 (1), 121-124, 2018 | 306 | 2018 |
| Complementary medicine, refusal of conventional cancer therapy, and survival among patients with curable cancers SB Johnson, HS Park, CP Gross, BY James JAMA oncology 4 (10), 1375-1381, 2018 | 298 | 2018 |
| Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation SL Galper, JB Yu, PM Mauch, JF Strasser, B Silver, A LaCasce, ... Blood, The Journal of the American Society of Hematology 117 (2), 412-418, 2011 | 281 | 2011 |
| Long-term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a phase II trial HM Kluger, V Chiang, A Mahajan, CR Zito, M Sznol, T Tran, SA Weiss, ... Journal of Clinical Oncology 37 (1), 52, 2019 | 228 | 2019 |
| Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases? RJ Colaco, P Martin, HM Kluger, BY James, VL Chiang Journal of neurosurgery 125 (1), 17-23, 2016 | 223 | 2016 |
| Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery JM Qian, JB Yu, HM Kluger, VLS Chiang Cancer 122 (19), 3051-3058, 2016 | 214 | 2016 |
| Association between geographic access to cancer care, insurance, and receipt of chemotherapy: geographic distribution of oncologists and travel distance CC Lin, SS Bruinooge, MK Kirkwood, C Olsen, A Jemal, D Bajorin, ... Journal of Clinical Oncology 33 (28), 3177, 2015 | 209 | 2015 |
| Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity JB Yu, PR Soulos, J Herrin, LD Cramer, AL Potosky, KB Roberts, ... Journal of the National Cancer Institute 105 (1), 25-32, 2013 | 203 | 2013 |
| Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity JB Yu, PR Soulos, J Herrin, LD Cramer, AL Potosky, KB Roberts, ... Journal of the National Cancer Institute 105 (1), 25-32, 2013 | 203 | 2013 |
| Prostate cancer radiation therapy recommendations in response to COVID-19 NG Zaorsky, BY James, SM McBride, RT Dess, WC Jackson, BA Mahal, ... Advances in radiation oncology 5, 26-32, 2020 | 178 | 2020 |
| Estimating survival in melanoma patients with brain metastases: an update of the graded prognostic assessment for melanoma using molecular markers (Melanoma-molGPA) PW Sperduto, W Jiang, PD Brown, S Braunstein, P Sneed, DA Wattson, ... International Journal of Radiation Oncology* Biology* Physics 99 (4), 812-816, 2017 | 178 | 2017 |
| Survival outcomes in atypical teratoid rhabdoid tumor for patients undergoing radiotherapy in a surveillance, epidemiology, and end results analysis DL Buscariollo, HS Park, KB Roberts, JB Yu Cancer 118 (17), 4212-4219, 2012 | 176 | 2012 |
| Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: comparison of toxicity BY James, LD Cramer, J Herrin, PR Soulos, AL Potosky, CP Gross Journal of clinical oncology 32 (12), 1195, 2014 | 164 | 2014 |
